GPNMB and melanoma: Glembatumumab Vedotin (GV), an antibody–drug conjugate (ADC) targeting GPNMB, is being investigated for treating breast (Vahdat et al, 2021) and lung (Khan et al, 2021) cancers, and in advanced melanoma.